Particle Therapy Market

The global particle therapy market size is expected to be valued at US$ 1.90 billion in 2026 and projected to reach US$ 3.36 billion by 2033, growing at a CAGR of 8.5% between 2026 and 2033.

Between 2020 and 2025, the market grew at a CAGR of about 7.2%, as pandemic delays were followed by new orders in Asia Pacific and Europe. Three factors now drive growth: rising cancer cases, strong clinical interest in sparing healthy tissue for children and hard-to-treat tumors, and smaller, cheaper compact proton systems that fit inside hospitals. The market is shifting from large multi-room centers toward single-room systems, pencil beam scanning, adaptive planning, and new delivery methods such as arc therapy and FLASH radiotherapy. Proton therapy dominates, while carbon ion therapy is expanding in Japan, China, and Europe. Upright treatment systems that rotate the patient instead of the beam promise further cost cuts.

• By Particle Type: Proton Therapy held 87.0% share in 2026, while Heavy Ion Therapy is projected to expand at a 10.8% CAGR through 2033, driven by new carbon ion centers in China, Japan, and South Korea.
• By System Type: Cyclotron-Based held 61.5% share in 2026, while Synchrocyclotron-Based is projected to expand at a 10.2% CAGR through 2033, driven by compact single-room systems for hospitals.
• By Cancer Type: Prostate Cancer held 23.8% share in 2026, while Pediatric Cancers are projected to expand at a 10.1% CAGR through 2033, driven by lower long-term side effects in children.
• By Region: North America held 45.0% share in 2026, while Asia Pacific is projected to expand at an 11.2% CAGR through 2033, driven by new centers in China, India, and Taiwan.

Two drivers carry the strongest influence on particle therapy demand during the forecast period.

Rising cancer cases and the tissue-sparing benefits of particle beams are the strongest driver of the particle therapy market. More patients need precise radiation that protects healthy organs.

The mechanism is the physical advantage of protons and heavy ions. Unlike X-rays, protons release most of their energy at a set depth, called the Bragg peak, and deliver almost no dose beyond the tumor. This lowers radiation to nearby organs such as the brain, heart, spinal cord, and growing tissues in children. Global cancer cases are expected to exceed 30 million a year by 2040, with about half of patients needing radiation. Proton therapy is preferred for pediatric tumors, brain and spine tumors, head and neck cancers, eye tumors, and re-irradiation. Clinical trials are testing benefits in breast, lung, esophageal, and liver cancers. These factors support steady growth in treatment rooms and patient volumes.

Compact, lower-cost proton systems are expanding the particle therapy market. Smaller machines make the technology affordable for more hospitals.

The cause is engineering progress that shrinks accelerators and gantries. Early proton centers cost more than US$ 150 million and needed large dedicated buildings. Single-room systems such as IBA’s Proteus ONE and Mevion’s S250-FIT cost a fraction of that and fit into existing radiation departments, with a typical Proteus ONE priced at €35 million to €45 million including maintenance. Superconducting synchrocyclotrons reduce size and power use. Leo Cancer Care’s upright Marie system rotates the patient instead of the beam, removing the need for a huge gantry. Pencil beam scanning improves precision and allows intensity-modulated proton therapy. These advances open the market to mid-sized hospitals.

Two restraints limit how quickly the particle therapy market grows.

High capital costs and long payback periods slow the particle therapy market. Particle therapy centers are among the most expensive medical facilities.

The specific causes are equipment, building, and staffing costs. Even compact single-room systems cost tens of millions of dollars, and multi-room proton or carbon ion centers can exceed US$ 200 million. Shielded concrete vaults, specialized power, and cooling add construction costs and years of building time. Centers need medical physicists, dosimetrists, and engineers with rare skills. Several United States proton centers faced financial difficulties and debt restructuring when patient volumes fell short of plans. High interest rates in 2023 to 2025 raised financing costs. Projects often take five or more years from contract to first patient. Rising construction and steel costs since 2022 have pushed budgets higher. These factors limit the number of new centers.

Limited reimbursement and evidence gaps restrict the particle therapy market. Payers question whether higher costs bring better outcomes for common cancers.

The underlying causes are high treatment prices and few large randomized trials. A course of proton therapy can cost much more than advanced X-ray therapy. Many private insurers in the United States deny coverage for prostate and breast cancer, citing limited comparative evidence. National health systems in Europe restrict access to approved indications. Ongoing trials may take years to report. Modern X-ray techniques such as intensity-modulated and stereotactic radiotherapy have narrowed the gap for some tumors. Prior authorization rules delay treatment starts and push some patients to X-ray therapy. Referral patterns depend heavily on local oncologists. These factors reduce patient referrals and slow center growth.

FLASH radiotherapy, proton arc therapy, and upright treatment open an innovation revenue pool in the particle therapy market. New techniques can improve outcomes and lower costs.

Vendors and research centers can capture this opportunity. FLASH radiotherapy delivers ultra-high dose rates in less than a second, which early studies suggest may spare healthy tissue even more. Proton arc therapy, such as IBA’s DynamicARC, rotates the beam during delivery for better dose shaping. Upright systems from Leo Cancer Care are being considered by IHH Healthcare in Asia Pacific and by Fosun in China. Adaptive planning with daily imaging improves accuracy. Software upgrades and service contracts provide recurring revenue. These innovations can widen indications, shorten treatment courses, and attract new customers. Research partnerships with universities help vendors build clinical evidence.

New centers in Asia Pacific and other emerging markets create a volume revenue pool in the particle therapy market. Many countries have few or no particle therapy centers.

Equipment makers with compact systems can capture this opportunity. China has approved many proton and carbon ion centers and has local makers such as Shinva and CGN. India has proton centers at Apollo Hospitals in Chennai and Tata Memorial in Mumbai, and more are planned. Taiwan ordered another IBA Proteus ONE in 2026. Brazil signed its first proton center contract in 2026. Governments see particle therapy as a way to keep patients from traveling abroad. Financing, leasing, and public-private partnerships help hospitals afford systems. Carbon ion therapy centers are also planned in China and South Korea, and training programs for physicists are expanding.

Proton Therapy held 87.0% share in 2026. Proton therapy is the most widely available form of particle therapy, with more than 100 centers in the United States and many in Europe, Japan, and China. It treats pediatric, brain, head and neck, eye, prostate, lung, and liver cancers. IBA, Varian, Hitachi, Mevion, and Sumitomo supply most systems. Single-room and multi-room centers are both growing.

Heavy Ion Therapy is the fastest-growing particle type, expanding at a 10.8% CAGR through 2033. Carbon ion therapy delivers more biological damage to tumors, making it useful for radioresistant cancers such as sarcomas and some pancreatic and head and neck tumors. Japan leads with several centers, and China, South Korea, Germany, Italy, and Austria have centers. For the market, heavy ion growth adds high-value projects.

Cyclotron-Based held 61.5% share in 2026. Isochronous cyclotrons with pencil beam scanning produce a steady proton beam and power most multi-room centers, including IBA’s Proteus PLUS and Varian’s ProBeam. They are reliable and support high patient volumes. Synchrotron-based systems from Hitachi and Mitsubishi Electric can vary energy directly and are used for both protons and carbon ions.

Synchrocyclotron-Based is the fastest-growing system type, expanding at a 10.2% CAGR through 2033. Superconducting synchrocyclotrons are small enough to mount on or near the gantry, powering compact proton systems such as Proteus ONE and Mevion S250. Lower costs suit hospitals with limited space. Many new orders in Asia Pacific, Europe, and Latin America are single-room systems. For the market, compact growth broadens access.

Prostate Cancer held 23.8% share in 2026. Prostate cancer is common and often treated with proton therapy in North America to reduce rectal and bladder side effects. Hypofractionated schedules shorten treatment and lower cost per patient. Brain, head and neck, lung, breast, and liver cancers form other large groups, and re-irradiation of recurrent tumors is a growing use.

Pediatric Cancers are the fastest-growing cancer type, expanding at a 10.1% CAGR through 2033. Children are especially sensitive to radiation, and protons reduce the risk of growth problems, hearing loss, learning difficulties, and second cancers. Guidelines in many countries recommend proton therapy for pediatric brain tumors, sarcomas, and other cancers. Brazil’s first center will focus on children. For the market, pediatric growth supports public funding.

North America is leading the particle therapy market with a 45.0% share in 2026. The United States has the largest number of proton centers in the world, including major programs at MD Anderson, Mayo Clinic, Massachusetts General Hospital, and Memorial Sloan Kettering. Varian, Mevion, and IBA have large installed bases. Medicare covers proton therapy for many indications, although private insurer coverage varies. Canada opened its first proton center in Montreal and is building more. New single-room systems are being installed in community hospitals, such as BayCare’s center in Florida. One change shaping the region is the move to compact systems.

Europe is a major particle therapy market. Germany, Italy, the United Kingdom, France, and the Netherlands have established proton and carbon ion centers, many linked to university hospitals. Spain is installing ten proton systems across nine sites under a public program funded by the Amancio Ortega Foundation. The United Kingdom runs national proton centers in Manchester and London. Austria’s MedAustron offers both protons and carbon ions. Denmark and Sweden run national proton centers. Key barriers include tight health budgets and strict indication lists. One opportunity is clinical research in FLASH and arc therapy.

Asia Pacific is growing fastest in the particle therapy market at an 11.2% CAGR through 2033. China is building many proton and carbon ion centers and supporting local manufacturers. Japan has one of the highest numbers of particle therapy centers per person in the world, with national insurance coverage for several cancers. India has a few centers and plans for more, serving patients from neighboring countries. Taiwan and South Korea are adding new systems, and Australia has opened its first proton center in Adelaide. One opportunity is upright and compact systems for hospital groups such as IHH Healthcare.

Latin America is an emerging particle therapy market. Brazil signed its first proton therapy center contract in 2026 for a pediatric-focused center in Rio de Janeiro, developed with the National Cancer Institute. Argentina is building a proton center in Buenos Aires with local technology partner INVAP. Mexico, Colombia, and Chile send patients abroad for treatment and are studying local centers. Families often travel to the United States or Europe at high cost. Key barriers include high costs, limited reimbursement, and shortages of trained physicists. One opportunity is pediatric-focused public centers built with development bank financing.

Middle East & Africa is an emerging particle therapy market. Saudi Arabia has opened proton therapy at King Fahad Medical City in Riyadh under its national health transformation plan, and the United Arab Emirates is planning centers to reduce medical travel abroad. Israel has strong research and clinical interest in compact and upright systems. South Africa has the region’s longest proton experience through iThemba LABS. Egypt and Qatar are studying centers for pediatric patients. Key barriers include high costs, limited insurance coverage, and few skilled staff. One opportunity is national cancer center projects that combine proton therapy with advanced imaging and research.

The particle therapy market is highly concentrated. IBA is the market leader by installed rooms, followed by Siemens Healthineers through Varian, Hitachi, Mevion Medical Systems, and Sumitomo Heavy Industries. Mitsubishi Electric, Toshiba Energy Systems & Solutions, ProTom International, Shinva, CGN, and Leo Cancer Care add competition, while software companies such as RaySearch Laboratories supply treatment planning.

Companies compete on clinical capabilities, footprint, cost, uptime, delivery techniques, service, and financing. Long-term maintenance contracts provide stable revenue after installation. Each contract is large, so a few wins can shift market share. Vendors often help customers with financing, site design, and staff training. Treatment planning software, imaging, and quality assurance tools are bundled into offers. Chinese makers are gaining share at home with government support.

Strategic moves show how competition is changing. In September 2025, Leo Cancer Care expanded its collaboration with IHH Healthcare to include upright proton therapy. In November 2025, Fosun partnered with Leo Cancer Care to bring upright particle therapy to China. In January 2026, IBA signed a Proteus ONE contract with MacKay Memorial Hospital in Taiwan. In June 2026, IBA signed a contract for Brazil’s first proton center. These moves show competition shifting toward compact systems and new geographies.

Three themes shape vendor strategy. First, vendors are shrinking systems to cut cost. Second, they are adding arc, adaptive, and FLASH capabilities. Third, they are expanding in Asia Pacific and Latin America.

• IBA
• Siemens Healthineers (Varian)
• Hitachi
• Mevion Medical Systems
• Sumitomo Heavy Industries

• June 2026: IBA signed a contract with Fundação Severino Sombra for a Proteus ONE system - creates Brazil’s first proton therapy center, focused on children.
• January 2026: IBA signed a contract to supply a Proteus ONE to MacKay Memorial Hospital in Taiwan - expands compact proton therapy in Asia Pacific.
• November 2025: Fosun partnered with Leo Cancer Care to bring upright particle therapy to China - supports lower-cost particle centers.
• September 2025: Leo Cancer Care expanded its collaboration with IHH Healthcare to include its Marie upright proton system - could widen proton access across Asia Pacific.

• IBA
• Siemens Healthineers (Varian)
• Hitachi
• Mevion Medical Systems
• Sumitomo Heavy Industries
• Mitsubishi Electric
• Toshiba Energy Systems & Solutions
• ProTom International
• Leo Cancer Care
• Shinva Medical Instrument
• China General Nuclear Power Group
• RaySearch Laboratories

This report covers particle therapy systems and services, including proton and heavy ion therapy, delivered by cyclotron, synchrocyclotron, and synchrotron systems in single-room and multi-room centers, for prostate, pediatric, brain, head and neck, lung, breast, liver, and other cancers in hospitals, cancer centers, and research institutes. It excludes conventional X-ray radiotherapy. The base year is 2025, and the forecast period runs from 2026 to 2033. All values are expressed in US$ Billion.

• Proton Therapy
• Heavy Ion Therapy

• Cyclotron-Based
• Synchrocyclotron-Based
• Synchrotron-Based

• Prostate Cancer
• Pediatric Cancers
• Brain & Head and Neck Cancers
• Lung & Breast Cancers
• Others

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

The particle therapy market is valued at US$ 1.90 billion in 2026, led by proton therapy systems and services in North America.

The particle therapy market is projected to reach US$ 3.36 billion by 2033, growing at an 8.5% CAGR and adding US$ 1.46 billion.

Heavy ion therapy is growing fastest at a 10.8% CAGR through 2033, driven by new carbon ion centers in China and Japan.

Asia Pacific is growing fastest at an 11.2% CAGR through 2033, driven by new centers in China, India, and Taiwan.

North America holds the largest share at 45.0% in 2026, supported by the world’s largest number of proton therapy centers.